MENU
+Compare
GERN
Stock ticker: NASDAQ
AS OF
Aug 28 closing price
Price
$1.43
Change
+$0.02 (+1.42%)
Capitalization
912.36M

GERN Geron Corp Forecast, Technical & Fundamental Analysis

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments... Show more

Industry: #Biotechnology
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GERN with price predictions
Aug 28, 2025

GERN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for GERN turned positive on August 05, 2025. Looking at past instances where GERN's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GERN's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

GERN moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GERN crossed bullishly above the 50-day moving average on August 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where GERN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GERN broke above its upper Bollinger Band on August 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GERN entered a downward trend on August 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.515) is normal, around the industry mean (19.700). P/E Ratio (0.000) is within average values for comparable stocks, (54.040). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.655). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (5.780) is also within normal values, averaging (303.721).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GERN is expected to report earnings to rise 28.00% to -2 cents per share on November 06

Geron Corp GERN Stock Earnings Reports
Q3'25
Est.
$-0.03
Q2'25
Beat
by $0.01
Q1'25
Est.
$-0.03
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.04
The last earnings report on August 06 showed earnings per share of -1 cents, beating the estimate of -2 cents. With 4.03M shares outstanding, the current market capitalization sits at 912.36M.
A.I. Advisor
published General Information

General Information

a developer of therapeutic products for cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
919 East Hillsdale Boulevard
Phone
+1 650 473-7700
Employees
141
Web
https://www.geron.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BERCX18.05N/A
N/A
Carillon Chartwell Mid Cap Value I
DQIYX34.61N/A
N/A
BNY Mellon Equity Income Fund Y
TADFX8.50N/A
N/A
Transamerica Sustainable Equity Inc R6
VEUVX39.68N/A
N/A
JPMorgan Europe Dynamic R6
ACIPX16.87N/A
N/A
American Century Mid Cap Value G

GERN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
+1.42%
SER - GERN
66%
Loosely correlated
+2.81%
LIANY - GERN
53%
Loosely correlated
N/A
VCYT - GERN
44%
Loosely correlated
+4.68%
SYRE - GERN
38%
Loosely correlated
-2.45%
UTHR - GERN
37%
Loosely correlated
+0.62%
More